Lilly Building On Gemzar Through Sanofi Oxaliplatin Joint Venture
Lilly plans to build its presence in the U.S. oncology market by adding Sanofi's colorectal cancer agent oxaliplatin to the pancreatic cancer therapy Gemzar (gemcitabine) under a joint venture agreement announced April 19.
You may also be interested in...
Sanofi-Synthelabo and co-marketing partner Bristol-Myers Squibb are discussing Phase III protocols in cardiac insufficiency for the angiotensin II inhibitor Avapro (irbesartan), Sanofi-Synthelabo COO Herve Guerin told an analysts meeting in London Sept. 2.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011